Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amit Gupta

Urology Los Angeles, CA Medical Doctor

NPI 1548464332 CMS profile 252241

8631 W 3Rd St Ste 531E, Los Angeles, CA 90048

Open in the dashboard

General payments

$50,277

132 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amit Gupta of Los Angeles, CA is reported in the CMS Open Payments database as having received $50,277 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,184 14
2024 General $2,928 8
2023 General $1,366 9
2022 General $21,274 20
2021 General $16,814 52
2020 General $2,879 10
2019 General $2,832 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amit Gupta
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Amit Gupta were reported at $2,184. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Amit Gupta Urology median Middle half National median
2019 $2,832 $480 $147–$1,201 $163
2020 $2,879 $246 $87–$645 $114
2021 $16,814 $358 $111–$1,000 $132
2022 $21,274 $476 $143–$1,263 $149
2023 $1,366 $560 $168–$1,461 $160
2024 $2,928 $563 $170–$1,464 $164
2025 $2,184 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $32,954 65 payments
  2. Ethicon Inc. $10,329 15 payments
  3. Johnson & Johnson Health Care Systems Inc. $2,000 2 payments
  4. PROCEPT BioRobotics Corporation $798 3 payments
  5. Gyrus ACMI, Inc. $730 1 payment
  6. Clinical Laserthermia Systems Americas Inc. $518 4 payments
  7. Medtronic, Inc. $357 3 payments
  8. Olympus America Inc. $315 3 payments
  9. Boston Scientific Corporation $209 4 payments
  10. Koelis Inc. $186 1 payment
  11. Other $1,881 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $18,285 6 payments
  2. Consulting Fee $11,607 6 payments
  3. Travel and Lodging $7,420 39 payments
  4. Food and Beverage $6,697 76 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,195 4 payments
  6. Grant $73 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $32,954 65 payments
  2. Velys Ortho-Knee $2,019 3 payments
  3. Velys Ortho-Hip $2,000 2 payments
  4. AQUABEAM ROBOTIC SYSTEM $748 2 payments
  5. URETERO-RENO VIDEOSCOPE $730 1 payment
  6. MOBILE LASER UNIT $518 4 payments
  7. INTERSTIM $357 3 payments
  8. iTIND System $315 3 payments
  9. Trinity $186 1 payment
  10. Monarch Platform $183 2 payments
  11. Other $1,712 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

513

Median for Urology: 1,053

Drug cost

$82,546

Median for Urology: $101,464

Branded share of claims

32.6%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 97 $68,840
Myrbetriq Mirabegron Brand 14 $9,190
Tamsulosin Hcl Generic 161 $1,968
Finasteride Generic 153 $1,948
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 18 $301
Oxybutynin Chloride Generic 15 $124
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 25 $82
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $65
Levofloxacin Generic 17 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 91 billing codes

Paid by Medicare

$448,034

Of which drugs: $208,345

Medicare patients

285

Average age 74

Services billed

8,652

59 women, 226 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 51%
Arthritis 47%
Cancer 42%
Diabetes 40%
Chronic kidney disease 30%
Heart failure 23%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record